HIV诊断时抗逆转录病毒耐药者的暴露前预防用药史:2015-2022年纽约市HIV监测与伴侣服务研究结果
研究利用纽约市监测与伴侣服务数据,评估PrEP用药史对2015-2022年新诊断HIV者基线M184I/V突变流行率的影响。在4246例新诊断且30天内获得基因型者中,近期PrEP使用者在有急性HIV感染(aRR 5.86,95%CI 2.49-13.77)和无急性HIV感染(aRR 7.26,95%CI 3.98-13.24)时M184I/V风险均高于无已知使用者。结论认为PrEP使用与基线M184I/V强相关,评估暴露后按指征检测核酸可减少未检测感染者的PrEP启动。
要点
- 4246例新诊断HIV者中98例(2%)携带M184I/V突变。
- 有急性HIV感染者中,近期PrEP使用较无已知使用者的M184I/V风险aRR为5.86(95%CI 2.49-13.77)。
- 无急性HIV感染者中,近期使用者aRR为7.26(95%CI 3.98-13.24),既往使用者aRR为4.46(95%CI 2.15-9.24)。
核心结论
- 在纽约市,无论是否合并急性HIV感染,PrEP使用史与诊断时基线M184I/V突变均呈强关联。
- 评估暴露、抗逆转录病毒用药史和急性HIV感染症状后按指征检测核酸,可减少未检测感染者的PrEP启动。
研究设计与样本
- 利用纽约市HIV监测与伴侣服务数据,纳入2015-2022年新诊断HIV者。
- 以诊断后30天内获得基因型者分析PrEP用药史(替诺福韦二吡呋酯/替诺福韦艾拉酚胺联合恩曲他滨)与基线M184I/V突变流行率的关联。
- PrEP使用分为近期(诊断前≤90天停药)、既往(诊断前>90天停药)和无已知使用;耐药突变用Stanford算法判定;采用对数二项回归生成校正相对风险(aRR)。
主要发现
- 4246例新诊断HIV且30天内获得基因型者中,560例(13%)有急性HIV感染,136例(3%)报告近期PrEP使用,124例(35%)报告既往PrEP使用,98例(2%)携带M184I/V。
- 有急性HIV感染者中,近期PrEP使用较无已知使用者的M184I/V风险aRR为5.86(95%CI 2.49-13.77)。
- 无急性HIV感染者中,近期使用者较无已知使用者的M184I/V风险aRR为7.26(95%CI 3.98-13.24),既往使用者较无已知使用者的aRR为4.46(95%CI 2.15-9.24)。
临床怎么用
- 作者认为,评估暴露、抗逆转录病毒用药史和急性HIV感染症状后按指征检测核酸,可减少未检测感染者的PrEP启动。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug resistance may be acquired in people starting human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) during undiagnosed infection. Population-based estimates of PrEP-related resistance are lacking. METHODS: We used New York City surveillance and partner services data to measure the effect of PrEP use (tenofovir disoproxil fumarate/tenofivir alafenamide fumarate with emtricitabine) history on the baseline prevalence of M184I/V mutations in people with HIV diagnosed in 2015-2022. PrEP use was categorized as "recent" (defined as PrEP stopped ≤90 days before diagnosis), "past" (PrEP stopped >90 days before diagnosis), or "no known use." Resistance-associated mutations were determined using the Stanford algorithm. We used log binomial regression to generate the adjusted relative risk (aRR) of M184I/V by PrEP use history in people with or without acute HIV infection (AHI). RESULTS: Of 4246 people with newly diagnosed HIV and a genotype obtained within ≤30 days of diagnosis, 560 (13%) had AHI; 136 (3%) reported recent and 124 (35%) past PrEP use; and 98 (2%) harbored M184I/V. In people with AHI, recent PrEP use was associated with a 6 times greater risk of M184I/V than no known use (aRR, 5.86 [95% confidence interval, 2.49-13.77]). Among people without AHI, the risk of M184I/V in recent users was 7 times that in people with no known use (aRR, 7.26 [95% confidence interval, 3.98-13.24]), and in past users, it was 4 times that in those with no known use (4.46 [2.15-9.24]). CONCLUSIONS: PrEP use was strongly associated with baseline M184I/V in New York City, regardless of AHI status. Ordering a nucleic acid test when indicated after assessment of exposure, antiretroviral history, and AHI symptoms can decrease PrEP initiation in people with undetected infection.
引用
- Misra K, Huang JS, Udeagu CN, et al. Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015-2022. Clin Infect Dis. 2024. PMID: 37976185. doi:10.1093/cid/ciad699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。